PTPRZ1 is activated by MDK, fueling cancer via the PI3K pathway, and blocking PTPRZ1 stopped cancer cell growth and spread, revealing PTPRZ1‐MDK as a new treatment target for LUSC. Here, PTPRZ1 is linked to cancer.